Fifth FDA/Alzheimer’s Disease Allies Meeting

ACT-AD, together with the Critical Path Institute, hosted an FDA/Alzheimer’s Disease Allies Meeting for patient groups, researchers and industry to interact with the FDA on how best to foster more robust pre-competitive collaboration in Alzheimer’s disease in order to encourage the development of combination therapies. This meeting explored the challenges of these collaborations and potential opportunities for future partnership.
View Agenda
View Meeting Report
View Article
View Transcript
Read Alzheimer Research Forum Series